Alan S. Livingstone
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Alan S. Livingstone has a total of 156 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Zaika
Sylvester Comprehensive Cancer Center, Miller School of Medicine at the University of Miami, Miami, Florida
19 shared publications - Dunfa Peng
Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
19 shared publications - Farah Ballout
Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA
19 shared publications - Heng Lu
Department of Surgery, Miller School of Medicine, University of Miami, Miami, FL, USA; Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, USA
19 shared publications - Lei Chen
School of Life Sciences, Qufu Normal University, Qufu 273165, China
19 shared publications - Nadeem Bhat
Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
19 shared publications
Latest Publications
- Open Access
- 28 August 2026
- Published by Elsevier in Translational Oncology
- Vol. 72
Modern therapeutic approaches in cholangiocarcinoma: A narrative review of key biomarkers and clinical trials
- 28 August 2026
- Published by Elsevier in Translational Oncology
- Vol. 72
Open AccessModern therapeutic approaches in cholangiocarcinoma: A narrative review of key biomarkers and clinical trials
- Open Access
- 12 February 2026
- Published by Elsevier in Journal of Vascular Surgery Cases, Innovations and Techniques
- Vol. 12 (3) , 102183
Open surgical resection of giant common hepatic artery aneurysm after failed endovascular repair
- 12 February 2026
- Published by Elsevier in Journal of Vascular Surgery Cases, Innovations and Techniques
- Vol. 12 (3) , 102183
Open AccessOpen surgical resection of giant common hepatic artery aneurysm after failed endovascular repair
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
Supplementary Figure 3. SMAD3 inhibition sensitizes oxaliplatin treated EAC cells to apoptosis.
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
Supplementary Figure 3. SMAD3 inhibition sensitizes oxaliplatin treated EAC cells to apoptosis.
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
Supplementary Figure 4. SMAD3 inhibition induces apoptosis in oxaliplatin sensitized EAC cells.
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
Supplementary Figure 4. SMAD3 inhibition induces apoptosis in oxaliplatin sensitized EAC cells.
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
Supplementary key resources table 1. Antibodies source and dilution
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
Supplementary key resources table 1. Antibodies source and dilution
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
Supplementary Figure 2. SMAD3 mediates resistance to oxaliplatin by regulating DNA damage/repair.
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
Supplementary Figure 2. SMAD3 mediates resistance to oxaliplatin by regulating DNA damage/repair.
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
Supplementary key resources table 1. Antibodies source and dilution
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
Supplementary key resources table 1. Antibodies source and dilution
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Data from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
Purpose:TGFβ signaling is implicated in the progression of most cancers, including esophageal adenocarcinoma (EAC). Emerging evidence indicates that TGFβ signaling is a key factor in the development of resistance toward cancer therapy.Experimental Design:In this study, we developed patient-derived organoids and patient-derived xenograft models of EAC and performed bioinformatics analysis combined with functional genetics to investigate the role of SMAD family member 3 (SMAD3) in EAC resistance to oxaliplatin.Results:Chemotherapy nonresponding patients showed enrichment of SMAD3 gene expression when compared with responders. In a randomized patient-derived xenograft experiment, SMAD3 inhibition in combination with oxaliplatin effectively diminished tumor burden by impeding DNA repair. SMAD3 interacted directly with protein phosphatase 2A (PP2A), a key regulator of the DNA damage repair protein ataxia telangiectasia mutated (ATM). SMAD3 inhibition diminished ATM phosphorylation by enhancing the binding of PP2A to ATM, causing excessive levels of DNA damage.Conclusions:Our results identify SMAD3 as a promising therapeutic target for future combination strategies for the treatment of patients with EAC.
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessData from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
Purpose:TGFβ signaling is implicated in the progression of most cancers, including esophageal adenocarcinoma (EAC). Emerging evidence indicates that TGFβ signaling is a key factor in the development of resistance toward cancer therapy.Experimental Design:In this study, we developed patient-derived organoids and patient-derived xenograft models of EAC and performed bioinformatics analysis combined with functional genetics to investigate the role of SMAD family member 3 (SMAD3) in EAC resistance to oxaliplatin.Results:Chemotherapy nonresponding patients showed enrichment of SMAD3 gene expression when compared with responders. In a randomized patient-derived xenograft experiment, SMAD3 inhibition in combination with oxaliplatin effectively diminished tumor burden by impeding DNA repair. SMAD3 interacted directly with protein phosphatase 2A (PP2A), a key regulator of the DNA damage repair protein ataxia telangiectasia mutated (ATM). SMAD3 inhibition diminished ATM phosphorylation by enhancing the binding of PP2A to ATM, causing excessive levels of DNA damage.Conclusions:Our results identify SMAD3 as a promising therapeutic target for future combination strategies for the treatment of patients with EAC.
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
Supplementary key resources table 2. Reagents and kits
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
Supplementary key resources table 2. Reagents and kits
- Open Access
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
Supplementary key resources table 3. Sequences of primers
- 15 May 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Targeting SMAD3 Improves Response to Oxaliplatin in Esophageal Adenocarcinoma Models by Impeding DNA Repair
Supplementary key resources table 3. Sequences of primers